Healthcare Services

A key trend shaping the Neuralgia Treatment Market involves the Innovative Products Drive Market Advancements In The Neuralgia Treatment Industry

April 2, 2026April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Neuralgia Treatment Market From 2026 To 2030?

The neuralgia treatment market has experienced robust expansion in recent years. It is projected to increase from $2.43 billion in 2025 to $2.58 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.1%. The historical growth of this market can be ascribed to factors such as the increasing incidence of diabetic neuropathy cases, the early adoption of anticonvulsant medications, the expansion of opioid-based pain treatment methods, heightened awareness of neuralgia symptoms, and the proliferation of hospital-based pain clinics.

The neuralgia treatment market size is projected to experience substantial expansion in the coming years, reaching $3.38 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.0%. This anticipated growth during the forecast period is fueled by several factors, including the rise in minimally invasive surgical pain interventions, a growing need for spinal cord stimulation devices, increased application of targeted topical therapies, the broadening of telemedicine services for neuralgia, and the creation of advanced non-opioid pain relief medications. Key developments expected in the forecast period encompass an expanding reliance on pharmaceutical approaches for neuralgia management, greater uptake of nerve block and decompression surgical techniques, an escalating demand for topical pain alleviation treatments, the wider deployment of spinal cord stimulation for persistent neuralgia conditions, and a heightened emphasis on prompt diagnosis coupled with sustained pain management strategies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12921&type=smp

What Key Drivers Are Influencing The Growth Of The Neuralgia Treatment Market?

The increasing incidence of long-term conditions, such as diabetes, is projected to fuel the expansion of the neuralgia treatment market in the future. These chronic diseases are health issues persisting for at least a year, requiring ongoing medical attention, limiting daily functions, or a combination of these. Diabetes, specifically, is an enduring metabolic disorder marked by elevated blood glucose, commonly known as blood sugar. Treatment for neuralgia can address diabetic neuropathy, which is nerve damage that may affect individuals with diabetes. As an illustration, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, showed that from March 2022 to March 2023, the proportion of people with type 1 diabetes undergoing all eight recommended care processes improved by 22%, and for type 2 diabetes, this figure rose by 21%. Concurrently, the proportion reaching target HbA1c levels climbed to 37.9%, representing the highest value ever recorded by the National Diabetes Audit (NDA). Consequently, the growing occurrence of chronic illnesses, particularly diabetes, is propelling the expansion of the neuralgia treatment market.

Which Segments Are Included In The Analysis Of The Neuralgia Treatment Market?

The neuralgia treatment market covered in this report is segmented –

1) By Treatment: Drug-Based, Surgeries

2) By Indication: Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia

3) By Distribution channel: Drug Stores, Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

4) By End-User: Hospitals And Clinics, Ambulatory Surgery Centers, Other End-Users

Subsegments:

1) By Drug-Based: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

2) By Surgeries: Nerve Block Procedures, Decompression Surgery, Neurectomy, Spinal Cord Stimulation

Which Trends Are Influencing The Neuralgia Treatment Market?

Leading companies active in the neuralgia treatment market are concentrating on developing advanced solutions, such as peripheral nerve-targeted delivery systems, aiming to enhance therapeutic precision, alleviate chronic neuropathic pain, and improve long-term patient outcomes. Peripheral nerve-targeted delivery systems are specialized therapeutic platforms that deliver analgesic or neuromodulatory agents directly to affected nerves, allowing for more accurate modulation of pain signals while minimizing systemic exposure. For instance, in April 2023, in India, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Shingrix, which stands as the world’s first non-live and recombinant subunit vaccine. This vaccine is formulated to prevent shingles and post-herpetic neuralgia in adults aged 50 years and older and requires intramuscular administration in two doses. Shingrix integrates the antigen glycoprotein E with the adjuvant system AS01B to generate a strong and sustained immunological response that assists in counteracting the immune system’s natural decline with age. Clinical trials have indicated that it is 97% effective in preventing shingles in adults. It also effectively prevents post-herpetic neuralgia, a painful complication often arising from shingles.

Which Key Industry Participants Are Active In The Neuralgia Treatment Market?

Major companies operating in the neuralgia treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Purdue Pharma, Dr. Reddy’s Laboratories, Cipla Limited, Hikma Pharmaceuticals plc, Zydus Lifesciences Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals, Glenmark Pharmaceuticals

Read the full neuralgia treatment market report here:

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Neuralgia Treatment Market?

North America was the largest region in the neuralgia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuralgia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neuralgia Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12921&type=smp

Browse Through More Reports Similar to the Global Neuralgia Treatment Market 2026, By The Business Research Company

Artificial Intelligence Ai Software Global Market Report

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-software-global-market-report

Ai Toolkit Global Market Report

https://www.thebusinessresearchcompany.com/report/ai-toolkit-global-market-report

Generative Ai Software Global Market Report

https://www.thebusinessresearchcompany.com/report/generative-ai-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795